中科院中亚药物研发中心乌兹别克斯坦落成,聚焦药品植物资源

2018-11-25 蔡国栋 新华社

新华社塔什干11月24日电 中国科学院中亚药物研发中心落成仪式23日在乌兹别克斯坦首都塔什干举行。同一天,中国科学院大学中亚科教基地也在塔什干挂牌成立。中国科学院院长白春礼说,该中心将成为中乌两国科技和教育合作的重要平台,在中亚地区药品植物资源的研究和可持续发展领域的科研交流、资源共享和人才培养方面发挥积极作用,也将促进中国与“一带一路”沿线国家科技合作,为沿线国家社会经济发展做出应有贡献。中国

新华社塔什干11月24日电 中国科学院中亚药物研发中心落成仪式23日在乌兹别克斯坦首都塔什干举行。同一天,中国科学院大学中亚科教基地也在塔什干挂牌成立。

中国科学院院长白春礼说,该中心将成为中乌两国科技和教育合作的重要平台,在中亚地区药品植物资源的研究和可持续发展领域的科研交流、资源共享和人才培养方面发挥积极作用,也将促进中国与“一带一路”沿线国家科技合作,为沿线国家社会经济发展做出应有贡献。

中国驻乌兹别克斯坦大使馆临时代办张汶川说,科技合作是中乌关系的重要组成部分,也是中乌共建“一带一路”的重要方向,相信中国科学院中亚药物研发中心将发挥技术引领作用,吸引更多国家参与合作,成为中国与“一带一路”沿线国家科技和创新合作的高端品牌。

中国科学院中亚药物研发中心以中亚区域特色天然产物药物研发为核心,是中国科学院“发展中国家科教合作拓展工程”在中亚布局的重要项目,是中国科学院建设的9个海外科教机构之一。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2056583, encodeId=76b8205658382, content=<a href='/topic/show?id=cc1ce3326fa' target=_blank style='color:#2F92EE;'>#研发中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73326, encryptionId=cc1ce3326fa, topicName=研发中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Mar 15 05:11:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745304, encodeId=98eb1e45304cd, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sun Aug 04 14:11:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862655, encodeId=3e411862655f7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Dec 03 09:11:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300211, encodeId=5914130021140, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301457, encodeId=75fd130145ef3, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2056583, encodeId=76b8205658382, content=<a href='/topic/show?id=cc1ce3326fa' target=_blank style='color:#2F92EE;'>#研发中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73326, encryptionId=cc1ce3326fa, topicName=研发中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Mar 15 05:11:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745304, encodeId=98eb1e45304cd, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sun Aug 04 14:11:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862655, encodeId=3e411862655f7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Dec 03 09:11:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300211, encodeId=5914130021140, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301457, encodeId=75fd130145ef3, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
    2019-08-04 xuyong535
  3. [GetPortalCommentsPageByObjectIdResponse(id=2056583, encodeId=76b8205658382, content=<a href='/topic/show?id=cc1ce3326fa' target=_blank style='color:#2F92EE;'>#研发中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73326, encryptionId=cc1ce3326fa, topicName=研发中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Mar 15 05:11:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745304, encodeId=98eb1e45304cd, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sun Aug 04 14:11:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862655, encodeId=3e411862655f7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Dec 03 09:11:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300211, encodeId=5914130021140, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301457, encodeId=75fd130145ef3, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
    2018-12-03 gous
  4. [GetPortalCommentsPageByObjectIdResponse(id=2056583, encodeId=76b8205658382, content=<a href='/topic/show?id=cc1ce3326fa' target=_blank style='color:#2F92EE;'>#研发中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73326, encryptionId=cc1ce3326fa, topicName=研发中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Mar 15 05:11:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745304, encodeId=98eb1e45304cd, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sun Aug 04 14:11:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862655, encodeId=3e411862655f7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Dec 03 09:11:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300211, encodeId=5914130021140, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301457, encodeId=75fd130145ef3, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=)]
    2018-11-27 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=2056583, encodeId=76b8205658382, content=<a href='/topic/show?id=cc1ce3326fa' target=_blank style='color:#2F92EE;'>#研发中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73326, encryptionId=cc1ce3326fa, topicName=研发中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Fri Mar 15 05:11:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745304, encodeId=98eb1e45304cd, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sun Aug 04 14:11:00 CST 2019, time=2019-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862655, encodeId=3e411862655f7, content=<a href='/topic/show?id=a121223385b' target=_blank style='color:#2F92EE;'>#中科院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22338, encryptionId=a121223385b, topicName=中科院)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Mon Dec 03 09:11:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300211, encodeId=5914130021140, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301457, encodeId=75fd130145ef3, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Tue Nov 27 12:11:00 CST 2018, time=2018-11-27, status=1, ipAttribution=)]

相关资讯

Nat Commun:中科院刘小龙研究组合作揭示调控造血干细胞髓系分化潜能的分子机制

国际学术期刊Nature Communications在线发表了中国科学院生物化学与细胞生物学研究所刘小龙研究组和四川大学华西医院郭帆研究组的最新研究成果“Med23 serves as a gatekeeper of the myeloid potential of hematopoietic stem cells”。该成果揭示了调控造血干细胞髓系分化潜能的分子机制。

Neuron:PDGFRβ细胞释放CCL2的生理功能

中国科学院神经科学研究所、脑科学与智能技术卓越创新中心、神经科学国家重点实验室于翔研究组在《神经元》期刊在线发表了题为“PDGFRβ Cells Rapidly Relay Inflammatory Signal from the Circulatory System to Neurons via Chemokine CCL2(PDGFRβ细胞通过趋化因子CCL2介导了外周感染信号向中枢神经系统的

Nat Cell Biol:中科院陈玲玲研究组首次揭示亚细胞结构paraspeckles和线粒体之间存在交流和相互作用

国际知名学术期刊Nature Cell Biology 在线发表了中国科学院生物化学与细胞生物学研究所陈玲玲研究组的最新研究成果“Genome-wide screening of NEAT1 regulators reveals cross-regulation between paraspeckles and mitochondria” (DOI: 10.1038/s41556-018-0204

PLOS Genet:中科院汪思佳研究组揭示影响眉毛浓密程度的遗传机制

国际学术期刊PLOS Genetics在线发表了中国科学院上海生命科学研究院(营养与健康研究院)计算生物学研究所汪思佳研究组名为“Genome-wide Association Studies and CRISPR/Cas9-mediated Gene Editing Identify Regulatory Variants Influencing Eyebrow Thickness in Hum

中科院报告:中国研究前沿度全球第二,但临床研究仅排13,“高血压强化降压治疗”研究最热

由中国科学院科技战略咨询研究院、中国科学院文献情报中心与科睿唯安联合发布了《2018研究前沿》报告和《2018研究前沿热度指数》报告。

Toxicol Sci:中科院武爱波研究组发现呕吐毒素致人源性细胞毒性相关的关键因子

国际学术期刊Toxicological Sciences在线发表了中国科学院上海生命科学研究院(营养与健康院)武爱波研究组题为“Transcription factor FOXO3a is a negative regulator of cytotoxicity of Fusarium mycotoxin in GES-1 cells”的最新研究成果,发现了呕吐毒素(DON)暴露致人胃黏膜上皮细胞